Summary
Resveratrol has reached Preclinical as its most advanced recorded development stage across any indication, and the database holds no approval for Type 2 Diabetes. ClinicalTrials.gov lists 8 registered trials linking Resveratrol to Type 2 Diabetes: 6 have completed; 2 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 2 (NCT06131918). It plans or enrolled 100 participants. Registration activity spans 2008 to 2023. The literature layer holds 13 publications for this pair: 5 Cochrane reviews, 2 meta-analyses, 1 systematic review and 5 clinical trial publications. Publication years run from 2021 to 2026. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
The RepurpOS disease-intelligence file for Type 2 Diabetes Mellitus ranks 767 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: 1.6-1.7% at 7 years on standard care (population-level cohorts UK and US).
Evidence table
| Evidence tier | C · Preliminary |
|---|---|
| Evidence score | 54.5 (trials 19.5, literature 30.0, tier 5, approved bonus 0.0) |
| Registered trials | 8 total: 0 recruiting, 0 active / not yet recruiting, 6 completed, 2 other |
| Linked publications | 13 (5 Cochrane reviews, 5 clinical trial publications, 2 meta-analyses, 1 systematic review) |
| Agent type | Supplement (Nutraceutical) |
| Development stage (any indication) | Preclinical |
| Mechanism / class | Potential dietary and lifestyle interventions for decreasing insulin resistance · Halma MTJ, Syed M, Marik PE · 2023 |
| Data sources | OSMF Chronic Disease Review |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT01451918 | Regulation of Intestinal and Hepatic Lipoprotein Secretion by Resveratrol 2011 | completed | Phase 2 | 8 |
| NCT06131918 | Assessment of Antioxidant Therapy on Oxidative Stress Biomarkers in Type 2 Diabetic Patients With Neuropathy 2023 | completed | Phase 2 | 100 |
| NCT02549924 | Effect of Administration of Resveratrol on Glycemic Variability in Individuals With Type 2 Diabetes Mellitus 2016 | terminated | Phase 2 | 22 |
| NCT02502253 | BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM) 2015 | completed | Phase 1 | 14 |
| NCT01302639 | Dietary Polyphenols and Lipid Oxidation 2011 | completed | Not applicable | 18 |
| NCT02129595 | Resveratrol and First-degree Relatives of Type 2 Diabetic Patients 2014 | completed | Not applicable | 15 |
| NCT01881347 | Effects of Resveratrol on Endothelial Function in Type 2 Diabetes Mellitus 2013 | completed | Not applicable | 54 |
| NCT01158417 | Resveratrol in Type2 Diabetes and Obesity 2008 | terminated | Not applicable | 15 |
Published literature
- Meta-analysis The effects of resveratrol on glycemic indices and lipid profile in patients with type 2 diabetes: an umbrella review and meta-analysisGhalichi F, Molani-Gol R, Tejareh F et al. · Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026 · PMID 42268476
- Meta-analysis Effects of resveratrol supplementation on multiple health outcomes: an umbrella review of systematic reviews and meta-analyses of randomized controlled trialsSun JN, Yang R, Fang L et al. · Nutrition journal · 2026 · PMID 41987155
- Systematic review The Role of Anthocyanins, Curcumin, and Resveratrol in the Prevention and Management of Metabolic Disorders: A Systematic ReviewGazda P, Glibowski P · Molecules (Basel, Switzerland) · 2026 · PMID 42280140
- Cochrane review A Systematic Review and Meta-Analysis of Randomized Controlled Trials on the Impact of Resveratrol Supplementation on Anthropometric Indices in Patients With Type 2 DiabetesLahouti M, Arzhang P, Azadbakht L · Phytotherapy research : PTR · 2025 · PMID 40842160
- Cochrane review Clinical Efficacy of Curcumin, Resveratrol, Silymarin, and Berberine on Cardio-Metabolic Risk Factors Among Patients With Type 2 Diabetes Mellitus: A Systemic Review and Bayesian Network Meta-AnalysisMiao R, Zhang B, Zhou D et al. · Phytotherapy research : PTR · 2025 · PMID 40439602
- Cochrane review The efficacy of resveratrol supplementation on inflammation and oxidative stress in type-2 diabetes mellitus patients: randomized double-blind placebo meta-analysisZhu P, Jin Y, Sun J et al. · Frontiers in endocrinology · 2024 · PMID 39872318
- Clinical trial publication Effect of Resveratrol on Markers of Oxidative Stress and Sirtuin 1 in Elderly Adults with Type 2 DiabetesGarcía-Martínez BI, Ruiz-Ramos M, Pedraza-Chaverri J et al. · International journal of molecular sciences · 2023 · PMID 37108584
- Clinical trial publication Effect of resveratrol supplementation on hepatic steatosis and cardiovascular indices in overweight subjects with type 2 diabetes: a double-blind, randomized controlled trialAli Sangouni A, Abdollahi S, Mozaffari-Khosravi H · BMC cardiovascular disorders · 2022 · PMID 35538431
- Clinical trial publication Role of resveratrol supplementation in regulation of glucose hemostasis, inflammation and oxidative stress in patients with diabetes mellitus type 2: A randomized, placebo-controlled trialMahjabeen W, Khan DA, Mirza SA · Complementary therapies in medicine · 2022 · PMID 35240291
- Clinical trial publication Resveratrol treatment does not reduce arterial inflammation in males at risk of type 2 diabetes: a randomized crossover trialBoswijk E, de Ligt M, Habets MJ et al. · Nuklearmedizin. Nuclear medicine · 2022 · PMID 34918332
- Cochrane review Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-AnalysisGu W, Geng J, Zhao H et al. · International journal of clinical practice · 2022 · PMID 35685602
- Cochrane review The effects of resveratrol on glycemic control and cardiometabolic parameters in patients with T2DM: A systematic review and meta-analysisAbdelhaleem IA, Brakat AM, Adayel HM et al. · Medicina clinica · 2022 · PMID 34666902
- Clinical trial publication The effects of resveratrol supplementation on PPARα, p16, p53, p21 gene expressions, and sCD163/sTWEAK ratio in patients with type 2 diabetes mellitus: A double-blind controlled randomized trialToupchian O, Abdollahi S, Salehi-Abargouei A et al. · Phytotherapy research : PTR · 2021 · PMID 33580595
Mechanism and notes
Recorded mechanism or class: Potential dietary and lifestyle interventions for decreasing insulin resistance · Halma MTJ, Syed M, Marik PE · 2023.
OSMF's existing evidence tier for this pair is C (Preliminary), derived from the strength of the disease association recorded in OSMF Chronic Disease Review. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Resveratrol approved for Type 2 Diabetes?
Resveratrol has reached Preclinical as its most advanced recorded development stage across any indication, and the database holds no approval for Type 2 Diabetes. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Resveratrol in clinical trials for Type 2 Diabetes?
ClinicalTrials.gov lists 8 registered trials linking Resveratrol to Type 2 Diabetes: 6 have completed; 2 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 2 (NCT06131918). It plans or enrolled 100 participants. Registration activity spans 2008 to 2023.
What does the evidence show for Resveratrol in Type 2 Diabetes?
Resveratrol has both completed registered trials and synthesis-level publications linked to Type 2 Diabetes. That is the strongest profile in this database, but the summaries here do not extract effect sizes, so read the linked reviews for direction and magnitude of benefit. OSMF's existing evidence tier for this pair is C (Preliminary), derived from the strength of the disease association recorded in OSMF Chronic Disease Review. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.